Valuation: Sernova Biotherapeutics Inc

Market Cap 52.87M 37.26M 32.67M 30.12M 28.19M 3.52B 53.97M 362M 140M 1.74B 140M 137M 6.02B P/E 2026 *
-4.67x
P/E 2027 * -3.5x
Enterprise Value 52.87M 37.26M 32.67M 30.12M 28.19M 3.52B 53.97M 362M 140M 1.74B 140M 137M 6.02B EV / Sales 2026 *
-
EV / Sales 2027 * 10.6x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -
1 week-6.67%
1 month-6.67%
3 months-15.15%
6 months+7.69%
Current year+7.69%
1 week 0.12
Extreme 0.12
0.16
1 month 0.12
Extreme 0.12
0.17
Current year 0.12
Extreme 0.12
0.2
1 year 0.12
Extreme 0.12
0.21
3 years 0.12
Extreme 0.12
1.04
5 years 0.12
Extreme 0.12
2.22
10 years 0.1
Extreme 0.095
2.87
Manager TitleAgeSince
Chief Executive Officer 58 12/08/2024
Director of Finance/CFO 60 11/10/2024
Investor Relations Contact - 11/10/2024
Director TitleAgeSince
Director/Board Member 60 19/04/2012
Director/Board Member - 24/04/2023
Director/Board Member - 01/09/2024
Date Insider Type Main position Quantity % Market Cap.
22/05Option

Director

260,000 0.0748%
22/05Option

Director

260,000 0.0748%
22/05Option

Director

173,418 0.0499%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-6.67%-15.15%-84.78% 37.25M
+5.25%+8.09%-14.78%+12.08% 121B
-0.65%+1.20%+3.41%-8.11% 12.85B
+1.30%+10.51%+42.91%+109.94% 8.37B
-3.88%-6.41%-50.34%-72.89% 3.95B
-0.38%-0.97%+17.98%+37.20% 2.53B
-9.06%+4.50%+229.48%+156.69% 1.7B
-8.75%-13.25%-26.46%-23.39% 1.68B
-2.80%-3.48%-1.78%-22.72% 1.57B
Average -2.11%-1.28%+20.58%+11.56% 17.1B
Weighted average by Cap. +3.82%+6.64%-7.79%+14.78%

Financials

2026 *2027 *
Net sales - 5M 3.52M 3.09M 2.85M 2.67M 332M 5.1M 34.23M 13.25M 164M 13.23M 12.94M 570M
Net income -12.83M -9.04M -7.93M -7.31M -6.84M -853M -13.09M -87.82M -33.98M -421M -33.95M -33.21M -1.46B -19.77M -13.94M -12.22M -11.26M -10.54M -1.31B -20.18M -135M -52.38M -650M -52.33M -51.18M -2.25B
Net Debt - -
Logo Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Employees
8
Date Price Change Volume
26/06/26 CAD 0.1400 0.00% 213,550
25/06/26 CAD 0.1400 0.00% 17,500
24/06/26 CAD 0.1400 -3.45% 208,654
23/06/26 CAD 0.1450 -6.45% 63,778
22/06/26 CAD 0.1550 +3.33% 78,770
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1400CAD
Average target price
0.4500CAD
Spread / Average Target
+221.43%

Quarterly revenue - Rate of surprise